Oxycodone: A pharmacological and clinical review

Clinical and Translational Oncology

Volumn 9, Issue 5, 2007, Pages 298-307

  Ordóñez Gallego, Amalio ^a   Gonzalez Baron M ^a   Espinosa Arranz, E ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Opioid; Oxycodone; Pain

Indexed keywords

ADENYLATE CYCLASE; ANALGESIC AGENT; BUPRENORPHINE; CODEINE; DRUG METABOLITE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOROXYCODONE; OPIATE; OXYCODONE; OXYMORPHONE; OXYNORM; PARACETAMOL; PLACEBO; NARCOTIC ANALGESIC AGENT;

ADJUVANT THERAPY; ANALGESIC ACTIVITY; ANOREXIA; BACKACHE; BIOEQUIVALENCE; BRONCHOSPASM; CANCER PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FOOD; HALLUCINATION; HUMAN; HYPERPOLARIZATION; IMMEDIATE RELEASE FORMULATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NIGHTMARE; OPIATE ADDICTION; OPIOID INDUCED EMESIS; OSTEOARTHRITIS; PLASMA PROTEIN BINDING; POSTOPERATIVE PAIN; PROLACTIN BLOOD LEVEL; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SLEEP; SLOW RELEASE FORMULATION; STRUCTURE ACTIVITY RELATION; SWEATING; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN; WITHDRAWAL SYNDROME; XEROSTOMIA; PAIN;

ANALGESICS, OPIOID; HUMANS; OXYCODONE; PAIN;

EID: 34848907462     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0057-9     Document Type: Review

References (73)

1. Cassinello J (2004) El dolor. Definición, tipos patogénicos, formas de presentación y evaluación del dolor. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic, S.L., Madrid
2. González Barón M, Ordóñez Gallego A (2003) Dolor y cáncer. Editorial Médica Panamericana, Madrid
3. González Barón M, Ordóñez Gallego A (2000) Dolor oncológico. Sentido del sufrimiento. In Ortiz JS (ed.) El control del sufrimiento evitable. Terapia analgésica. You and Us, S.A., Madrid
4. Ordóñez Gallego A, González Barón M (2004) Oxicodona: Nuevo opioide. Revista de Oncología 6:203-206
5. Domínguez G, Gómez Sancho M, Verd M, Brennan LD (2004) Oxicodona, una opción en el manejo del dolor desde 1917. Medicina Paliativa 11:246-263
6. Ordóñez A, González Barón M, Feliu J et al (2001) Tratamiento de soporte en el enfermo con cáncer. Algunas propuestas basadas en nuestra experiencia. Revista de Oncología 3:266-269
7. Ordóñez A, De Castro J, Espinosa E et al (2003) Transdermal fentanyl treatment in opioid-naïve cancer patients. Revista de Oncología 5:162-165
8. Escudero P, Ordóñez A, Cassinello J (2003) Initial doses of fentanyl-TTS based on pain intensity with cancer pain. Thirty-Ninth Annual Meeting ASCO, Chicago, abst. 3123
9. Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63-67
10. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: A structure-related activity study. Br J Pharmacol 121:834-840
11. Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be k-opioid receptor mediated. Pain 73:151-157
12. Smith MT, Ross FB, Nielsen CK, Saini K (2001) Oxycodone has a distinctly different pharmacology from morphine. Eur J Pain 5[Suppl A]:135-136
13. Varga J, Dickerson ED, Davis MP (2001) United States prescribing habits: what's going on? (abstract) Support Care Cancer 9:311
14. Falk E (1917) Eukodal, ein neues narkotikum. Munch Med Wochenschr 20:381-384
15. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:S3-S13
16. Levy MH (2001) Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 5[Suppl A]:113-116
17. Evans PJD (1999) Controlled-release oxycodone: Do we need another opiate analgesic? Eur J Pain 3:67-68
18. Colucci RD, Swanton RE, Gordon ThB, Kaiko RF (2001) Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther 8:231-236
19. Benziger DP, Kaiko RF, Miotto JB et al (1996) Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 85:407-410
20. Davis M, Wilcock A (2001) Modified-release opioids. Eur J Palliat Care 8:142-146
21. Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-611
22. Leow KP, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 80:296-302
23. Kaiko RF, Benzinger DP, Fitzmartin RD et al (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52-61
24. Davis MP, Varga J, Dickerson D et al (2003) Normal-release and controlled-release oxycodone: Pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84-92
25. Poyhia R, Seppala T, Oikkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone alter intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617-621
26. Flórez J, Reig E (1993) Terapéutica farmacológica del dolor. Ediciones Universidad de Navarra S.A., Pamplona
27. Belda C, Fresno JA, Ceja P, González Barón M (2003) Bases moleculares de la respuesta a los opioides. In Ordóñez Gallego A, González Barón M (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., Madrid
28. Watson PN, Babul N (1998) Efficacy of oxycodone in neuropathic pain a randomized trial in postherpetic neuralgia. Neurology 58:1837-1841
29. Hale ME, Fleischman R, Salzman R et al (1999) Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 15:179-183
30. Kampe S, Warm S, Kaufmann J et al (2004) Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Curr Med Res Opin 20:199-202
31. Hagen N, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled release oxycodone formulation and controlled release hydromorphone in the treatment of cancer pain. Cancer 79:1428-1437
32. Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37-45
33. Citron M, Kaplan R, Parris W et al (1998) Long-term administration of controlled release oxycodone tablets for the treatment of cancer pain. Cancer Invest 16:562-571
34. Mucci-LeRusso P, Berman BS, Silberstein PT et al (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double blind, parallel-group study. Eur J Pain 2:239-249
35. Bruera E, Belzile M, Pituskin E (1998) Randomized, double blind cross over trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 16:3222-3229
36. Kaplan R, Parris W, Citron M et al (1998) Comparison of controlled-release and immediate release oxycodone tablets in patients with cancer pain. J Clin Oncol 16:3230-3237
37. Parris W, Johnson B, Croghan M et al (1998) The use of controlled release oxycodone for the treatment of chronic cancer pain: A randomised, double-blind study. J Pain Symptom Manage 16:205-211
38. Salzman R, Roberts M, Wild J et al (1999) Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18:271-279
39. Stambaugh JE, Reder RF (2001) Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled-and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 41:500-506
40. Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027-2030
41. Ripamonti C, Dickerson D (2001) Strategies for the treatment of cancer pain in the New Millennium. Drugs 61:955-977
42. Ross FB, Wallis SC, Smith MT (2000) Co-administration of sub-antinociceptive synergy with reduced CSN side-effects in rats. Pain 84:421-428
43. Riley J, Ross J, Rutter D et al (2006) No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 14:56-64
44. Watson CPN, Moulin D et al (2003) Controlledrelease oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 105:71-78
45. Gimbel J, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 60:894-895
46. Finnerup NB, Otto M, McQuay HJ et al (2005) Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 118:289-305
47. Wallsch TM (2002) Oxycodone retard in a patient suffering form a polyneuropathy with burning dysaesthesia. Neurol Rehabil 8:208-210
48. Roth SH et al (2000) Around the clock, controlled-release oxycodone therapy for osteoarthritis related pain. Placebo controlled trial and long term evaluation. Arch Intern Med 160:853-860
49. Ytteberg SR, Mahowald ML, Woods SR (1998) Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 41:1603-1612
50. Caldwell JR, Hale ME, Boyd RE et al (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862-869
51. McCroskery E, Croft J, Markenson J et al (2000) 3-month efficacy and safety study of OxyContin in osteoarthritis patients. Proceedings of EFIC, Sep 26-29, Nice, France
52. Markeson JA, Croft J, Zhang PG et al (1996) Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone. Br J Clin Pharmacol 42:747-756
53. Zautra AJ, Bruce BW (2005) Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 21:471-477
54. Gammaitoni AR et al (2003) Effectiveness and safety of new oxycodone/ acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 4:21-30
55. Überall MA, Mueller-Schwefe G (2005) Untreated pain-optimizing multidisciplinary rehabilitation programs in high-risk patients with chronic low back pain using WHO-III opioid oxycodone. Abstracts, 11th World Congress on Pain
56. Krämer J (2005) Effective and safe treatment of lumbar root compression syndrome with sustained-release oxycodone. Abstracts, 11th World Congress on Pain
57. Reuben SS, Connelly NR, Maciolek H (1999) Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 88:1286-1291
58. Cheville A, Chen A, Oster G et al (2001) A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg 83A:572-576
59. Wirz S et al (2005) Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopaedic surgery: a prospective, randomized, double-blind investigation. Pain Clin 17:367-376
60. de Beer JdeV, Winemaker MJ, Donnelly GA et al (2005) Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg 48:277-283
61. Hohwü L, Akre O, Bergenwald L et al (2006) Oral oxycodone hydrochloride versus epidural anaesthesia for pain control after radical retropubic prostatectomy. Scand J Urol Nephrol 40:192-197
62. Staal C, Drenes AM (2004) Experimental human pain models: A review standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 95:97-111
63. Sorensen TR, Staal C, Arendt-Nielsen L et al (2006) Differential effects of opioids in patients with chronic pancreatitis. An experimental pain study. Digestive Disease Week, Los Angeles, USA, 2006. Poster no. 223486
64. Staal C, Christrup LL, Andersen SD et al (2006) A comparative study of oxycodone and morphine in a multimodal, tissue differentiated experimental pain model. Pain 123:28-36
65. Bezinger D, Kaiko R, Mohito J et al (1996) Differential effects of food on the bioavailability of controlled release oxycodone tablets and immediate release oxycodone solution. J Pharm Sci 58:407-410
66. Borrás JL, Rodríguez D, Lafuerza A (2004) Manejo del dolor complejo. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic S.L., Madrid
67. Vilches Y, De Luis V, González Barón M (2003) Rotación de opioides. In González Barón M, Ordóñez Gallego A (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., Madrid
68. Hanks GW, De Conno F, Cherny N et al (2002) Morfina y opiáceos alternativos para el tratamiento del dolor oncológico. Medicina Paliativa 9:22-29
69. Rischitelli G, Karbowicz SH (2002) Safety and efficacy of controlled-release oxycodone: A systematic literature review. Pharmacotherapy 22:898-904
70. Maddocks I, Somogyi A, Abbott F et al (1996) Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12:182-189
71. Davis M, Tailcock A (2001) Modified-release opioids. Eur J Palliative Care 8:142-146
72. Ripamonti C, Bruera E (1997) CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 8:21-37
73. Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a Mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65:252-257